Faruqi & Faruqi Reminds Fractyl Investors of Securities Class Action Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (NASDAQ: GUTS) and has reminded investors of the October 20, 2026, deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The firm is urging investors who purchased or acquired securities in Fractyl between January 13, 2025, and January 29, 2026, to contact partner Josh Wilson directly to discuss their legal rights.

According to the complaint, Fractyl and its executives are alleged to have violated federal securities laws by making false and misleading statements and failing to disclose key information. The lawsuit claims that the company overstated the effectiveness of its investigational treatment, Revita, and that operational issues at one or more clinical sites compromised the integrity of the REMAIN-1 Midpoint Cohort's efficacy results. This, the complaint argues, overstated the clinical, regulatory, and commercial prospects of Revita.

On January 30, 2026, the stock price fell further by $0.125, or 21.37%, after Canaccord Genuity and Morgan Stanley downgraded the company. Morgan Stanley cut its price target to $2.00 from $8.00, characterizing the results as "disappointing."

Faruqi & Faruqi, LLP, which has recovered hundreds of millions of dollars for investors since its founding in 1995, is encouraging anyone with information regarding Fractyl's conduct to contact the firm. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who directs and oversees the litigation on behalf of the putative class.

Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Participation in a class action does not affect an investor's ability to share in any recovery obtained on behalf of the class.